Editor’s note

  • The pharma play in Ayushman Bharat

    With saturation in export markets and rising regulatory constraints, will we see a refocus on the domestic market, prodded by schemes like Ayushman Bharat?

  • India’s FDC saga and other stories

    Framing regulations is one thing, interpreting and implementing them quite another saga, allowing repeat offenders like Biomed to remain below the radar for too long

  • Putting the bite into our laws

    The recent faulty hip implant episode proves that our laws have not evolved as fast as medical technology

  • Revitalising pharmacy education

    While there are good intentions, it is the implementation which threatens the viability of  initiatives like the Pharm D course With September 5, Teachers’ Day around the corner, Express...

  • Playing for global stakes

    Most bigger pharma companies have moved to the next level of exports: the trade of intellectual property, in the form of clinical stage assets in return for milestone payments...

  • Will indigenisation, innovation and information lead to true independence?

    In my Editors Note in last year's Independence Day special issue, I had asked: as we mark our 71st Independence Day this August 15, how far have we progressed...

  • Acing the value chain

    It is ironical that a Chinese movie seems to have done what India's policy makers have been trying to do for many years: get China to lower the barriers...

  • Cracking down on fake medicines

    One of the important proposals considered during the 79th Drug Technical Advisory Board (DTAB) meeting held on May 16 was the introduction of a trace and track feature on...

  • Halol haze lifts, finally

    It’s time to count the learnings from Halol, both internally for Sun Pharma as well as for India Pharma Inc

  • Putting all patients first

    In a speech on May 12, US President Donald Trump put one of his most populist election promises — to make medicines more affordable for the US citizens —...

  • Diving deeper into pharma GMP

    For the past two years, the May 16-31 edition of Express Pharma has been a GMP Special issue, highlighting topics crucial to quality in pharma...

  • Lessons from Orchid Pharma’s story

    The task force on APIs is too late to rescue Orchid Pharma but will hopefully prevent more API makers from burning out.

  • Mozambique tightens pharma export process

    From March 15, Mozambique mandated pre shipment testing of pharma exports, choosing to start with India, which is its largest supplier of pharma products.

  • Yet another go at FDCs?

    We seem to be slowly but surely moving towards the Centre’s goal of substituting branded medicines with generics

  • Going beyond cosmetic changes

    The 40 odd transfers of drug inspectors/ technical officers that followed Dr Eswara Reddy's appointment as DCG(I) have not impressed industry veterans like Dr Ajit...

  • A spring cleaning at the CDSCO?

    February saw a fairly massive churn in India's drug regulatory infrastructure

  • India Pharma Inc’s place in Modicare

    Pharma companies will have to come up with strategies to play a meaningful role in the NHPS

  • Countering India Pharma Inc’ Achilles heel

    India’s drug regulator, the Drug Controller General India (DCGI), should be cheered by a recent report from India Ratings and Research (Ind-Ra), that seems to...

  • Sabke Saath, Pharma ka bhi Vikas?

    All eyes are now on Finance Minister Arun Jaitley as he readies to present the Union Budget 2018-19, most probably on February 1

  • It’s Centre vs states, once again

    AIDCOC says the proposed joint inspections of pharma manufacturing facilities by drug inspectors of the state and centre will lead to “dual control...delay and undue...

  • Will 2018 be the turning point?

    Besides analysing the past, we need to plan for the future

  • Time for a new strategy?

    According to a recently released CII report, “Indian Roots, American Soil,” the life sciences, pharmaceuticals, and healthcare sector is the second largest group of Indian...

  • Who’s next, after Torrent-Unichem?

    After a search that reportedly lasted a decade, Unichem Laboratories finally settled on Torrent Pharma as the best choice to sell its domestic branded formulations...

  • Converting growth potential into a reality

    This year's CPhI Annual Report released a ranking of countries as pharmaceutical destinations on various parameters

  • Balancing volumes with value

    When the going gets tough, the tough get going. This adage could well describe the beleaguered pharma exporters of India

  • What ails India’s pharma exports?

    It is no secret that declining pharmaceuticals exports have been worrying not just pharma honchos but the Prime Minister’s Office as well

  • A double whammy for the sector?

    As expected, the August 30 meeting called by the Department of Pharmaceuticals (DoP) to discuss the Draft Pharmaceutical Policy 2017 saw a laundry list of...